Dr Aaron Lisberg is a thoracic medical oncologist at the University of California, Los Angeles (UCLA). He specialises in novel drug development, antibody-drug conjugates (ADCs), immunotherapy, and metabolically targeted therapies in patients with advanced malignancies, focusing on lung cancer. He is board-certified in hematology and medical oncology.

 

Dr Lisberg received his medical degree from the University of Minnesota Medical School, where he was elected to the AOA honor society. He then completed his internal medicine residency at The University of Washington in Seattle and his hematology/oncology fellowship at UCLA.

 

Dr Lisberg conducts translational research on novel therapeutic approaches in advanced malignancies, specifically focusing on lung cancer. He has a wide range of ongoing research projects, including the evaluation of factors predictive of response or toxicity to antibody-drug conjugates (ADCs) and immune checkpoint inhibitors, pre-clinical/clinical evaluation of novel metabolic therapies, and assessment of effective treatments in patients with targetable tumor alterations. He is also the clinical PI and Sub-I of several clinical trials evaluating novel therapeutics in various malignancies, including Phase I, II, and III assessments.

Dr Aaron Lisberg has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Commercial Research Grants:  AstraZenca, Calithera Biosciences, Daiichi Sankyo, Dracen Pharmaceuticals, Duality Biologics, eFFECTOR Therapeutics, Seagen (Pfizer), WindMIL, BioNTech

 

Consultation/Advisory Board:  Abbvie, Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb, Daiichi Sankyo, Eli-Lilly, G1 Therapetuics, Gilead Services, IQVIA, Janssen Pharmaceuticals, Jazz Pharmaceuticals, Leica Biosystems, Molecular Axiom, MorphoSys, Novartis, Novocure, Oncocyte, Pfizer, Regeneron, Sanofi group of companies, Whitehawk Therapeutics

 

Travel only: Duality Biologics, BioNTech

 

Stocks, shares or equity: Wife an employee of Boston Scientific with stock (<5% equity), stock (<5% equity) Paralos Bioscience